Asset Details
Do you wish to reserve the book?
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Do you wish to request the book?
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012
Overview
In the treatment of patients with acute pulmonary embolism, the efficacy of rivaroxaban, a factor Xa inhibitor, was similar to that of traditional anticoagulation therapy. There was less bleeding in the group receiving rivaroxaban, which supports its use in the treatment of this condition.
Pulmonary embolism is a common disease, with an estimated annual incidence of 70 cases per 100,000 population.
1
,
2
The condition usually leads to hospitalization and may recur; it can be fatal.
3
For half a century, the standard therapy for most patients with pulmonary embolism has been the administration of heparin, overlapped and followed by a vitamin K antagonist.
4
,
5
This regimen is effective but complex.
5
–
9
Recently developed oral anticoagulants that are directed against factor Xa or thrombin overcome some limitations of standard therapy, including the need for injection and for regular dose adjustments on the basis of laboratory monitoring. . . .
Publisher
Massachusetts Medical Society,Massachussetts Medical Society
Subject
/ Aged
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Biological and medical sciences
/ Bleeding
/ Cardiovascular & respiratory systems
/ Embolism
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ International Normalized Ratio
/ Male
/ Morpholines - adverse effects
/ Morpholines - therapeutic use
/ Patients
/ Pulmonary Embolism - drug therapy
/ Pulmonary Embolism - mortality
/ Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
/ Sciences de la santé humaine
/ Systèmes cardiovasculaire & respiratoire
/ Thiophenes - adverse effects
